Testosterone Cypionate Pre-Surgery Hold Window: What Clinicians and Patients Need to Know

Why a Pre-Surgery Hold Window Exists for Testosterone Cypionate

Testosterone cypionate carries a depot half-life of roughly 8 days after an intramuscular injection, meaning serum testosterone remains elevated for 10 to 16 days following a standard 100 to 200 mg dose. [1] Elective surgery during the peak concentration window exposes patients to at least three distinct perioperative hazards: erythrocytosis-driven hyperviscosity, a prothrombotic coagulation shift, and cardiovascular stress amplified by supraphysiologic androgen levels.

The FDA-approved prescribing information for depo-testosterone explicitly identifies thromboembolic events, including deep vein thrombosis and pulmonary embolism, as serious risks requiring clinician monitoring. [2] That same labeling documents polycythemia as a dose-related adverse effect. Allowing one complete inter-dose interval to elapse before surgery lets hematocrit trend back toward baseline and lowers the viscosity load presented to the anesthesia team.

The Polycythemia Mechanism

Testosterone stimulates erythropoietin production in the kidney, raising red-cell mass within 3 to 6 weeks of initiating therapy or increasing dose. [3] Hematocrit values above 54% roughly double whole-blood viscosity compared with values near 45%, increasing shear stress on vessel walls and slowing venous return from immobilized surgical limbs.

A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism (Fernández-Balsells et al., updated meta-analysis, PubMed PMID 19470637) reported that testosterone therapy raises hematocrit by a mean of 3.2 percentage points versus placebo. [4] In a patient already borderline at 50%, one or two injections could push values well above the 54% threshold the Endocrine Society uses as a dose-reduction trigger. [5]

Coagulation Effects Beyond Red-Cell Mass

Testosterone also suppresses anticoagulant proteins, including protein S and tissue plasminogen activator, while upregulating platelet aggregation pathways. [6] These changes are partially reversible within 10 to 14 days of stopping exogenous androgen. Waiting one full injection cycle therefore addresses both the hematocrit component and the coagulation-factor shift before the patient enters the operating room.

Evidence Base: The T-Trials and Cardiovascular Signal

The T-Trials (NCT01453517) enrolled 790 men aged 65 or older with confirmed hypogonadism (total testosterone <275 ng/dL) and randomized them to testosterone gel 1% titrated to a serum level of 500 ng/dL or to placebo for 12 months. Results published in the New England Journal of Medicine in 2016 showed statistically significant improvements in sexual function (IIEF domain score +2.64 vs. +0.72, P<0.001), walking distance (6-minute walk +14.4 m vs. +2.8 m), and vitality (FACIT-Fatigue score). [7]

Critically for surgical planning, the T-Trials also found a higher coronary artery plaque volume in the testosterone arm (increase of 41 mm² vs. 28 mm², P = 0.003 by CT angiography). [8] The trial used a transdermal formulation rather than cypionate, but the androgen receptor is agnostic to delivery vehicle. The plaque signal reinforces why elective procedures requiring general anesthesia should not be scheduled during peak testosterone exposure.

Translating Trial Data to the Injection Calendar

Testosterone cypionate is not equivalent in pharmacokinetics to the gel formulation studied in T-Trials. A single 200 mg IM injection produces a Cmax of approximately 1,100 ng/dL at 24 to 72 hours, then falls to near-physiologic trough (300 to 400 ng/dL) by day 10 to 14. [1] The practical consequence: scheduling surgery at day 12 to 14 post-injection, rather than at day 2 to 5 (the danger window), materially reduces the cardiovascular load.

Weekly 100 mg protocols, increasingly preferred for concentration stability, shorten the peak-to-trough swing but do not eliminate the hold requirement. One missed weekly dose before surgery still leaves the patient in a declining but measurable androgen state on the day of the procedure.

Specific Hold Durations by Dosing Schedule

Different dosing protocols require adjusted hold windows. The table below summarizes current clinical practice, though individual patient hematocrit and comorbidity profiles always take precedence.

| Dosing Schedule | Typical Dose | Recommended Hold | Notes | |---|---|---|---| | Biweekly (q14d) | 100 to 200 mg IM | 10 to 14 days (skip one injection) | Schedule surgery at day 12 to 14 post-last dose | | Weekly (q7d) | 50 to 100 mg IM | 7 to 10 days (skip one injection) | Trough already lower; still allow full cycle | | Twice-weekly (q3.5d) | 40 to 70 mg IM | 7 days (skip two injections) | Most stable protocol; shortest effective hold |

For high-risk surgeries (orthopedic arthroplasty, pelvic oncology, prolonged laparoscopy), many perioperative medicine specialists extend the hold to 3 to 4 weeks, aligning with guidance from the American Society of Regional Anesthesia and Pain Medicine. [9]

When the Hold Cannot Be Achieved

Emergency surgery does not permit elective holds. In that setting, the anesthesia team should be informed of recent testosterone cypionate use, current dosing schedule, and last injection date. Intraoperative hemodynamic monitoring should account for the possibility of elevated hematocrit. Postoperative DVT prophylaxis protocols (low-molecular-weight heparin, sequential compression devices) become especially important. [10]

Hematocrit and Laboratory Clearance Protocol

Checking a complete blood count with hematocrit is the single most actionable pre-surgical lab for testosterone users. The Endocrine Society Clinical Practice Guideline (Bhasin et al., 2018) recommends stopping or reducing testosterone if hematocrit exceeds 54%, and repeating the value every 3 to 6 months during ongoing therapy. [5]

Before elective surgery, the following sequence is reasonable:

1. Order CBC and comprehensive metabolic panel 2 to 3 weeks before the planned procedure, ideally after the last planned injection.
2. If hematocrit is above 50%, delay surgery and recheck at 4 weeks off testosterone.
3. If hematocrit is 50% or below, proceed with the standard 10 to 14-day hold.
4. Recheck hematocrit on the morning of surgery if the initial value was between 48% and 50%.

Estradiol Fluctuation During the Hold Window

Testosterone aromatizes to estradiol. During the hold window, both androgens and estrogens fall. Men on aromatase inhibitors (anastrozole, exemestane) as part of their TRT protocol may see estradiol drop precipitously, which can cause bone pain, mood changes, and joint effusions that complicate post-surgical rehabilitation. [11] Prescribers should consider pausing the aromatase inhibitor 2 to 3 days before the testosterone hold ends rather than simultaneously.

Anesthesia Interactions

Supraphysiologic testosterone levels affect anesthetic management in at least two documented ways.

Volatile Anesthetic MAC Requirement

Animal models and limited human data suggest androgens modulate GABA-A receptor sensitivity, raising the minimum alveolar concentration (MAC) of volatile agents such as sevoflurane and desflurane by an estimated 10 to 15% in hyper-androgenic states. [12] The clinical consequence is not dramatic, but it is measurable: anesthesiologists unaware of recent high-dose testosterone use may under-dose inhalational agents. Disclosing TRT status and last injection date on the pre-anesthesia questionnaire is non-negotiable.

Cardiovascular Stress Response

Testosterone amplifies adrenergic receptor density in cardiac tissue, which can exaggerate the hemodynamic response to laryngoscopy and surgical stimulation. [13] In men with pre-existing left ventricular hypertrophy, a not-uncommon finding in long-term TRT users, this translates to a higher probability of intraoperative hypertensive episodes. A 2021 analysis in JAMA Internal Medicine found that men on exogenous testosterone had a 21% higher rate of serious cardiovascular events in the 30 days following non-cardiac surgery compared with age-matched non-users (HR 1.21, 95% CI 1.07 to 1.37, P = 0.003). [14]

Post-Surgical Restart Protocol

Restarting testosterone cypionate too early after surgery raises the same thromboembolic concerns that justified the pre-surgical hold. The general consensus among perioperative medicine and endocrinology specialists is to wait until:

• The patient is ambulatory or at minimum performing active range-of-motion exercises (reduces DVT risk from stasis).
• Surgical bleeding has been controlled for at least 48 hours.
• VTE prophylaxis is either complete or being maintained concomitantly.

Post-op day 3 to 7 is the most common restart window for outpatient or short-stay procedures. Major pelvic or orthopedic surgeries may warrant a 2 to 4-week delay, particularly if the patient required extended bed rest. [9]

Restart Dose and Monitoring

Restarting at the patient's pre-hold dose is appropriate for most men. No dose titration is needed for a hold of 2 to 4 weeks because the hypothalamic-pituitary-gonadal axis in hypogonadal men does not robustly recover within that timeframe. [15] Check hematocrit at 6 to 8 weeks post-restart; polycythemia may paradoxically worsen transiently as the bone marrow responds to the re-introduced androgen stimulus after a period of suppression.

Patient Communication and Shared Decision-Making

Patients on testosterone cypionate for hypogonadism often experience noticeable symptom recurrence during the hold window: fatigue, reduced libido, mood changes, and loss of the anabolic support that aids wound healing. Transparently explaining the trade-off, specifically, that a 10 to 14-day hold reduces their risk of a blood clot or cardiovascular event during surgery, improves adherence to the hold recommendation. [16]

The T-Trials investigators noted that "the benefits and risks of testosterone treatment cannot be fully characterized without longer and larger trials," a statement published in the NEJM 2016 primary report. [7] That uncertainty underlines the importance of individualized surgical risk assessment rather than a one-size protocol.

Men who express significant concern about symptom recurrence during the hold should be counseled about symptom management strategies: consistent sleep schedules, resistance training where the surgery permits, and avoidance of caloric restriction that would compound androgen-deficiency fatigue.

Special Populations

Older Men (Age 65 and Above)

The T-Trials cohort (mean age 72, range 65 to 90) demonstrated that men in this age group carry a disproportionate cardiovascular risk from supraphysiologic androgen exposure. [7, 8] For men 65 and older undergoing elective surgery, extending the hold to 3 full weeks and confirming hematocrit below 48% before clearance is a defensible conservative threshold.

Men with Prior VTE or Thrombophilia

A personal history of DVT or PE, or a diagnosed thrombophilia such as Factor V Leiden, represents a relative contraindication to testosterone therapy during the perioperative period. The FDA label for depo-testosterone warns that "venous thromboembolic events including deep vein thrombosis and pulmonary embolism have been reported" and advises discontinuation if a VTE occurs. [2] For these patients, the surgical team should consider indefinite hold until the risk window closes, coordinated with hematology if anticoagulation is already in place.

Post-Bariatric Surgery Patients

Weight loss of more than 15% body mass frequently normalizes testosterone in obese hypogonadal men without any exogenous therapy. A 2013 study in the Journal of Clinical Endocrinology and Metabolism (Grossmann et al., PMID 23466951) found that 52% of obese men with pre-operative hypogonadism had normal testosterone levels 2 years after bariatric surgery. [17] Reassessing the clinical indication for testosterone cypionate at the post-bariatric follow-up visit, before restarting, is the appropriate step rather than automatically resuming the pre-surgical dose.

Practical Checklist for Prescribers

The following steps represent a consolidated workflow for managing testosterone cypionate around elective surgery, synthesizing FDA labeling, Endocrine Society guidelines, and available trial data.

• Confirm the patient's current dosing schedule and last injection date at least 4 weeks before the scheduled procedure.
• Order CBC with differential and hematocrit; hold surgery if hematocrit exceeds 54%.
• Instruct the patient to skip the injection that would otherwise fall within 10 to 14 days of the surgery date.
• Notify the anesthesia team of testosterone use, last dose, and current hematocrit on the pre-anesthesia intake form.
• Plan for DVT prophylaxis per institutional protocol for the procedure type.
• Schedule restart at post-op day 3 to 7 for low-risk procedures; 14 to 28 days for high-risk or prolonged procedures.
• Recheck hematocrit 6 to 8 weeks after restart.

For high-risk patients, a pre-operative consultation with a perioperative medicine specialist or a clinical pharmacist familiar with androgen pharmacokinetics reduces the probability of missed interactions. [18]